Idursulfase
From Wikipedia, the free encyclopedia
|
Idursulfase
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | A16 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Idursulfase (brand name Elaprase) is a drug used to treat Hunter syndrome (also called Mucopolysaccharoidosis II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced. Initial yearly costs were reported to be $300,000.[2]
It is manufactured by Shire Pharmaceuticals Group.
[edit] References
- ^ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:. PMID 17459751.
- ^ Drug approved to treat rare but potentially deadly disease. Retrieved on 2007-09-02.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
